Previous Page  22 / 42 Next Page
Information
Show Menu
Previous Page 22 / 42 Next Page
Page Background

Pain Management 2018

Internal Medicine 2018

International Journal of Anesthesiology & Pain Medicine

ISSN: 2471-982X

Page 73

March 26-28, 2018

Vienna, Austria

JOINT EVENT

7

t h

E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n

Internal Medicine and Patient Care

&

6

t h

E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n

Pain Management

Volume 4

9

0% of parasites produce myocarditis.

Ascaris lumbricoides

(Round worm)

Ancylostoma duodenale

, (Hook worms)

Enterobius vermicularis (Pin worm, Thread worm ) Loa loa

(African eye worm),

Wuchereria bancrofti

(Filarial worm),

Dracunculus medinensis

(Guinea worm),

Trichuris trichiura

(Whip

worm),

Trichinella spiralis

(Trichina worm)

Dirofilaria

(Dog heart

worm),

Taenia solium

(Pig tape worm),

Taenia saginata

(Beef tape

worm),

Diphyllobothrium latum

(Fish tape worm),

Echinococcus

granulosus

(Dogtapeworm),

Hymenolepisnana

(Dwarftapeworm),

Schistosoma haematobium

(Blood fluke),

Fasciola hepatica

(Liver

fluke),

Paragonimus westermani

(Lung fluke),

Protozoan parasites

like

Entamoeba histolytica

,

Trypanosoma cruzi

, Trypanosoma

gambiense,

Toxoplasma gondii

etc. Parasites produce a toxic and

allergic manifestation that leads to myocarditis, cardiomyopathy,

acute heart failure, elevation of myocardial infarction, cardiogenic

shock, neglected tropical diseases such as hidden cause of cardio

vasculardiseaseetc.Butyetparasitesareignoredbycardiologists,

clinicians and scientists. The parasites produce toxic metabolites

and increase hypereosinophilic. These toxic metabolites and

eosinophils will show the following adverse effects on heart.

They damage heart myocytes, neuronal damage, micro vascular

damage and direct cell mediated damage. Hyaline degeneration

of muscle and produce continuous antigenic stimulation. These

metabolites produce tropical pulmonary eosinophilia and tropical

endomyocardial fibrosis. Eosinophils induce tissue damage.

The idiopathic hypereosinophilia syndrome damages the heart

tissue may cause a direct effect on various structures of heart

like myocardium, endocardium, cardiac vasculature and resulting

in congestive heart failure, cardiomyopathy, tachycardia, cardiac

murmurs,muffledheart sounds.The invadingparasitescanattach

and multiply in the heart. Some parasites produce cardio toxin.

The toxin degenerate DNA and produces myocardial dysfunction

and complete heart block. Conductive tissue of heart is severely

damaged. Because of cytolysis and necrosis protein synthesis is

blocked. The parasites and migratory larvae may attack normal or

prosthetic valves. Obstruction of blood flow occurs. Myocarditis

is most often due to a parasitic infection. Parasitic infections may

cause inflammation of heart muscle (myocarditis) with temporary

or potentially permanent damage to heart muscles cells leading

to a secondary cardiomyopathy occur when the heart muscle

fibers are abnormally stretched when the heart chambers

increase in size and volume. Heart damage is extensive. Immune

system continues to damage heart. Significant impairment of

heart function occurs. Parasites cause myocarditis, paralyze the

nerve supply to myocardium of heart and damage heart bicuspid

and tricuspid valves. As a result, angina, chest, arm, neck, upper

back pain, irregular beats, shortness of breath (SOB) occur.

The parasites will continue to emerge leading to unpredictable

epidemics and challenges for the clinicians and scientists. Hence

there is an urgent need of surveillance and control, advance

diagnostics, tests, vaccines, therapeutics and development of

new drugs are needed. Most drugs in the pipeline have failed in

clinical trials.

reachdrmvrrao@gmail.com

Cardiac manifestations of parasitic infections

M V Raghavendra Rao, Sireesha Bala A, Sateesh Arja A, Samir Fatteh, Abraham

Ratna Joseph

and

Amin Fatteh

Avalon University School of Medicine, Curacao

Int J Anesth Pain Med 2018, Volume 4

DOI: 10.21767/2471-982X-C1-003